Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. News about ImmuCell often centers on sales performance for its First Defense® product line, strategic decisions regarding its Re-Tain® mastitis treatment candidate, and updates on manufacturing capacity and financing.
Investors following ICCC news can expect regular preliminary, unaudited product sales updates shortly after quarter-end, followed by detailed unaudited financial results releases. These announcements typically include commentary on product sales trends for First Defense®, including Tri-Shield® and Dual-Force® variants, domestic and international sales mix, gross margin performance, and the impact of prior production backlogs and inventory rebuilding.
Company news also covers strategic shifts, such as ImmuCell’s decision to focus resources on expanding the First Defense® franchise after receiving an FDA Incomplete Letter for the Re-Tain® New Animal Drug Application. Releases describe plans to increase the First Defense® sales force, expand manufacturing capacity, repurpose assets, and complete investigational Re-Tain® studies to support potential licensing or partnership opportunities.
Additional ICCC news items include leadership changes, such as the selection and onboarding of a new President and CEO, bank debt refinancing transactions, extensions of credit facilities, and details of conference calls with investors. For readers tracking ICCC, this news feed provides a centralized view of operational updates, product development milestones, capital structure developments and management commentary related to ImmuCell’s cattle health business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ImmuCell Corporation (Nasdaq: ICCC) announced preliminary sales results for Q1 2023, reporting $3.45 million, a decline of 43% from $6.00 million in Q1 2022. The decrease is attributed to a production slowdown due to previously disclosed contamination issues. The backlog of orders increased significantly to $7.5 million from $2.5 million at the end of 2022. Efforts during the slowdown included process improvements and complete sanitization of production facilities. Quality control tests have shown an 82% pass rate for incoming milk batches. The company is preparing for a third submission to the FDA for the Re-Tain® product by end of April 2023, with a six-month review period expected. A conference call is scheduled for May 12, 2023, to discuss full financial results.
ImmuCell Corporation (Nasdaq: ICCC) reported its unaudited financial results for the year ended December 31, 2022, showing a net loss of $2.5 million compared to a net loss of $78,000 in 2021. The gross margin fell to 41% from 45% due to contamination issues in production. The company faced production slowdowns and increasing backlogs, which reached $2.5 million. Cash reserves decreased to $5.8 million, down from $10.2 million in the prior year. Despite setbacks, ImmuCell is focused on expanding production capacity while preparing to resubmit critical FDA documentation for its Re-Tain® product, which addresses significant losses from subclinical mastitis in the dairy industry.
ImmuCell Corporation (Nasdaq: ICCC) has announced its upcoming unaudited financial results for the year ending December 31, 2022, to be released after the market closes on February 21, 2023. A conference call will follow on February 22, 2023, at 9:00 AM ET for discussing these results. Investors can participate by calling (844) 855-9502 or (412) 317-5499. The Company also plans to file its Annual Report on Form 10-K around March 29, 2023, and will update its Corporate Presentation on its website.
ImmuCell is known for products that enhance cattle health, including First Defense® and the developing Re-Tain® treatment.
ImmuCell Corporation (Nasdaq: ICCC) announced its preliminary, unaudited sales results for 2022, showing total sales of $18.57 million, down 3.5% from $19.24 million in 2021. Q4 sales were $3.91 million, a 28.2% decline compared to $5.44 million in Q4 2021. Notably, the company reported a backlog of $2.5 million, significantly up from $205,000 in Q3 2022. Despite production delays, the company aims to obtain regulatory approval for its Re-Tain product in 2023.
ImmuCell Corporation (Nasdaq: ICCC) will report its unaudited financial results for Q3 2022 after market close on November 21, 2022. A conference call is scheduled for 9:00 AM ET on November 22, 2022, to discuss these results. The company is restating its financial statements for Q1 and Q2 2022 due to an error that understated administrative expenses by approximately $222,000. This restatement does not affect its cash position or product sales. Preliminary sales results for Q3 are expected to remain unchanged.
ImmuCell Corporation (Nasdaq: ICCC) has reported preliminary, unaudited sales results for Q3 2022, indicating total sales of $4.80 million, down 7% from $5.15 million in Q3 2021. For the nine-month period, sales rose to $14.66 million, up 6% from $13.80 million in 2021. The company has reduced its backlog significantly, from $2.43 million to approximately $205,000. CEO Michael Brigham expressed optimism about ongoing production improvements and regulatory submissions for the product Re-Tain, expected to proceed in early 2023.